OVID - Ovid Therapeutics: Lack Of Clear Efficacy Signals Do Not Look Convincing

Ovid Therapeutics Inc. (OVID) is a recently IPO-ed pharmaceutical company, established in 2014, IPO-ed in 2017. It targets unmet need in neurological diseases. Currently, they have 4 drugs in their pipeline, with one drug reaching its pivotal trial. OV101 or Gaboxadol, the lead drug, targets a rare neurological disease, Angelman syndrome. This disease affects approximately 16360 to 27000 patients all over the US. There is no FDA-approved drug to treat this disease. Drugs available in the market only reduce certain symptoms, but do not cure it.

Typically, this disease is caused by mutation